Corticotropin-releasing Hormone Stimulates NF-kappaB in Human Epidermal Keratinocytes

Overview

Journal J Endocrinol

Specialty Endocrinology

Date 2004 Jun 3

PMID 15171702

Citations 30

Authors

Blazej Zbytek

Lawrence M Pfeffer

Andrzej T Slominski

Affiliations

Soon will be listed here.

Abstract

Corticotropin-releasing hormone (CRH) has been shown to inhibit proliferation and modulate expression of inflammation markers in the epidermal cells. In the present study we report that CRH also stimulates nuclear factor-kappa B (NF-kappaB) activity. Incubation with CRH of human keratinocytes derived from primary cultures resulted in increased binding of DNA by NF-kappaB. CRH induced translocation of NF-kappaB subunit p65 from the cytoplasm to the nucleus and induced expression of kappaB-driven chloramphenicol acetyltransferase (CAT) reporter gene. NF-kappaB translocation was accompanied by degradation of the inhibitor of NF-kappaB alpha (IkappaB-alpha). Specificity of the CRH effect was demonstrated by the use of CRH-R antagonists antalarmin and alpha-helical CRH [9-41]. CRH-dependent stimulation of NF-kappaB activity is consistent with accumulated data about role of this neuropeptide in the regulation of local epidermal homeostasis.

Citing Articles

The brain-skin axis in vitiligo.

Cao C, Lei J, Zheng Y, Xu A, Zhou M Arch Dermatol Res. 2024; 316(8):607.

PMID: 39240376 DOI: 10.1007/s00403-024-03362-w.

Anti-Fibrotic Effects of RF Electric Currents.

Hernandez-Bule M, Toledano-Macias E, Perez-Gonzalez L, Martinez-Pascual M, Fernandez-Guarino M Int J Mol Sci. 2023; 24(13).

PMID: 37446165 PMC: 10341950. DOI: 10.3390/ijms241310986.

Neuroendocrine signaling in the skin with a special focus on the epidermal neuropeptides.

Slominski A, Slominski R, Raman C, Chen J, Athar M, Elmets C Am J Physiol Cell Physiol. 2022; 323(6):C1757-C1776.

PMID: 36317800 PMC: 9744652. DOI: 10.1152/ajpcell.00147.2022.

Transcriptomic analysis reveals myometrial topologically associated domains linked to the onset of human term labour.

Tyagi S, Chan E, Barker D, McElduff P, Taylor K, Riveros C Mol Hum Reprod. 2022; 28(3).

PMID: 35150271 PMC: 8903000. DOI: 10.1093/molehr/gaac003.

The Brain-Skin Axis in Psoriasis-Psychological, Psychiatric, Hormonal, and Dermatological Aspects.

Marek-Jozefowicz L, Czajkowski R, Borkowska A, Nedoszytko B, Zmijewski M, Cubala W Int J Mol Sci. 2022; 23(2).

PMID: 35054853 PMC: 8776235. DOI: 10.3390/ijms23020669.

References

Seitz C, Deng H, Hinata K, Lin Q, Khavari P . Nuclear factor kappaB subunits induce epithelial cell growth arrest. Cancer Res. 2000; 60(15):4085-92. View

Slominski A, Wortsman J, Luger T, Paus R, Solomon S . Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. Physiol Rev. 2000; 80(3):979-1020. DOI: 10.1152/physrev.2000.80.3.979. View

Slominski A, Szczesniewski A, Wortsman J . Liquid chromatography-mass spectrometry detection of corticotropin-releasing hormone and proopiomelanocortin-derived peptides in human skin. J Clin Endocrinol Metab. 2000; 85(10):3582-8. DOI: 10.1210/jcem.85.10.6863. View

Yang C, Murti A, Pfeffer S, Basu L, Kim J, Pfeffer L . IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc Natl Acad Sci U S A. 2000; 97(25):13631-6. PMC: 17627. DOI: 10.1073/pnas.250477397. View

Quevedo M, Slominski A, Pinto W, Wei E, Wortsman J . Pleiotropic effects of corticotropin releasing hormone on normal human skin keratinocytes. In Vitro Cell Dev Biol Anim. 2001; 37(1):50-4. DOI: 10.1290/1071-2690(2001)037<0050:peocrh>2.0.co;2. View

FREEDBERG I, Tomic-Canic M, Komine M, Blumenberg M . Keratins and the keratinocyte activation cycle. J Invest Dermatol. 2001; 116(5):633-40. DOI: 10.1046/j.1523-1747.2001.01327.x. View

Slominski A, Wortsman J, Pisarchik A, Zbytek B, Linton E, Mazurkiewicz J . Cutaneous expression of corticotropin-releasing hormone (CRH), urocortin, and CRH receptors. FASEB J. 2001; 15(10):1678-93. DOI: 10.1096/fj.00-0850rev. View

Qin J, Bacon P, Chaturvedi V, Nickoloff B . Role of NF-kappaB activity in apoptotic response of keratinocytes mediated by interferon-gamma, tumor necrosis factor-alpha, and tumor-necrosis-factor-related apoptosis-inducing ligand. J Invest Dermatol. 2001; 117(4):898-907. DOI: 10.1046/j.0022-202x.2001.01477.x. View

Pisarchik A, Slominski A . Alternative splicing of CRH-R1 receptors in human and mouse skin: identification of new variants and their differential expression. FASEB J. 2001; 15(14):2754-6. DOI: 10.1096/fj.01-0487fje. View

10.

Zbytek B, Mysliwski A, Slominski A, Wortsman J, Wei E, Mysliwska J . Corticotropin-releasing hormone affects cytokine production in human HaCaT keratinocytes. Life Sci. 2002; 70(9):1013-21. DOI: 10.1016/s0024-3205(01)01476-x. View

11.

Li Q, Verma I . NF-kappaB regulation in the immune system. Nat Rev Immunol. 2002; 2(10):725-34. DOI: 10.1038/nri910. View

12.

Zhao J, Karalis K . Regulation of nuclear factor-kappaB by corticotropin-releasing hormone in mouse thymocytes. Mol Endocrinol. 2002; 16(11):2561-70. DOI: 10.1210/me.2001-0334. View

13.

Dajee M, Lazarov M, Zhang J, Cai T, Green C, Russell A . NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature. 2003; 421(6923):639-43. DOI: 10.1038/nature01283. View

14.

Wiesner B, Roloff B, Fechner K, Slominski A . Intracellular calcium measurements of single human skin cells after stimulation with corticotropin-releasing factor and urocortin using confocal laser scanning microscopy. J Cell Sci. 2003; 116(Pt 7):1261-8. DOI: 10.1242/jcs.00301. View

15.

Mempel M, Voelcker V, Kollisch G, Plank C, Rad R, Gerhard M . Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol. 2003; 121(6):1389-96. DOI: 10.1111/j.1523-1747.2003.12630.x. View

16.

Zbytek B, Pfeffer L, Slominski A . Corticotropin-releasing hormone inhibits nuclear factor-kappaB pathway in human HaCaT keratinocytes. J Invest Dermatol. 2003; 121(6):1496-9. PMC: 1201435. DOI: 10.1111/j.1523-1747.2003.12612.x. View

17.

Singh V . Stimulatory effect of corticotropin-releasing neurohormone on human lymphocyte proliferation and interleukin-2 receptor expression. J Neuroimmunol. 1989; 23(3):257-62. DOI: 10.1016/0165-5728(89)90058-1. View

18.

Barker J, Mitra R, Griffiths C, Dixit V, Nickoloff B . Keratinocytes as initiators of inflammation. Lancet. 1991; 337(8735):211-4. DOI: 10.1016/0140-6736(91)92168-2. View

19.

Singh V, Leu S . Enhancing effect of corticotropin-releasing neurohormone on the production of interleukin-1 and interleukin-2. Neurosci Lett. 1990; 120(2):151-4. DOI: 10.1016/0304-3940(90)90025-5. View

20.

Hagan P, Poole S, Bristow A . Immunosuppressive activity of corticotrophin-releasing factor. Inhibition of interleukin-1 and interleukin-6 production by human mononuclear cells. Biochem J. 1992; 281 ( Pt 1):251-4. PMC: 1130669. DOI: 10.1042/bj2810251. View